all report title image

Acute Bacterial Skin And Skin Structure Infections Market, By Drug Type (Oral & Parenteral Antibiotics and Topical Antibiotics), By Infection Type (Hospital Acquired ABSSSI and Community Acquired ABSSSI), By Route of Administration (Oral, Parenteral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

  • Published In : May 2024
  • Code : CMI1531
  • Pages :180
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical
Ingographics Image

Global acute bacterial skin and skin structure infections market is estimated to be valued at USD  3,842.5 Mn in 2024, and is expected to exhibit a CAGR of 5.8% during the forecast period (2024-2031). Acute bacterial skin and skin structure infections (ABSSSI) refer to common bacterial infections that involve the skin and surrounding tissue or structures such as major cutaneous abscesses, cellulitis, and infected wounds or ulcers. Some of the common bacteria that cause ABSSSI include Staphylococcus aureus and Streptococcus pyogenes. With rising antibiotic resistance and increasing risk factors such as obesity, diabetes, and lifestyle changes, the global incidence of ABSSSI increases.

Market Dynamics:

Growing geriatric population worldwide coupled with rising prevalence of comorbidities such as diabetes increases the risk of ABSSSI. According to the International Diabetes Federation, approximately 463 million adults aged 20-79 years lived with diabetes in 2019, and this figure is projected to rise to over 700 million by 2045. The elderly are also more susceptible to skin and soft tissue infections. Rapid urbanization and changes in lifestyle that compromise immune health have further increased the ABSSSI disease burden globally. However, stringent regulations pertaining to clinical trials and drug approvals can hinder the market growth. Ongoing R&D for novel antibacterial medications and rapid adoption of advanced wound care therapies offers lucrative opportunities in the market.

Key Features of the Study:

  • This report provides an in-depth analysis of the global acute bacterial skin and skin structure infections market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
  • It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global acute bacterial skin and skin structure infections market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this includes Fresenius SE & Co. KGaA, Pfizer, Inc., Amneal Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd, GSK plc, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., AbbVie, Inc., Melinta Therapeutics, Inc., Accord Healthcare Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Paratek Pharmaceuticals, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • Global acute bacterial skin and skin structure infections market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute bacterial skin and skin structure infections market.

Detailed Segmentation-

  • By Drug Type:
    • Oral & Parenteral Antibiotics
      • Oritavancin
      • Delafloxacin
      • Vancomycin
      • Others
    • Topical Antibiotics
      • Hydrogen Peroxide
      • Fusidic Acid
      • Mupirocin
      • Retapamulin
  • By Infection Type:
    • Hospital Acquired ABSSSI
    • Community Acquired ABSSSI
  • By Route of Administration:
    • Oral
    • Parenteral
    • Topical
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa

Company Profiles:

  • Fresenius SE & Co. KGaA
  • Pfizer, Inc.
  • Amneal Pharmaceuticals LLC
  • Intas Pharmaceuticals Ltd.
  • Cadila Healthcare Ltd.
  • Glenmark Pharmaceuticals Ltd
  • GSK plc
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd.
  • AbbVie, Inc.
  • Melinta Therapeutics, Inc.
  • Accord Healthcare Ltd.
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Paratek Pharmaceuticals, Inc.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Drug Type
      • Market Snapshot, By Infection Type
      • Market Snapshot, By Route of Administration
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Regulatory Scenario
    • Manufacturer Revenue
    • Adoption of Non-invasive Sensor Technologies
    • Acquisitions and Partnerships Scenario
    • Product Launches/Approvals
    • Funding and Investments
    • PEST Analysis
    • Porter’s Analysis
  4. Global Acute Bacterial Skin and Skin Structure Infections Market- Impact of Coronavirus (COVID-19) Pandemic
    • Overall Impact
    • Government Initiatives
    • COVID-19 Impact on the Market
  5. Global Acute Bacterial Skin and Skin Structure Infections Market, By Drug Type, 2019 – 2031, (USD Mn)
    • Overview
      • Market Share Analysis, 2024 and 2031 (%)
      • Y-o-Y Growth Analysis, 2019 – 2031
      • Segment Trends
    • Oral & Parenteral Antibiotics
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD Mn)
        • Oritavancin
        • Delafloxacin
        • Vancomycin
        • Others
    • Topical Antibiotics
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD Mn)
        • Hydrogen Peroxide
        • Fusidic Acid
        • Mupirocin
        • Retapamulin
  6. Global Acute Bacterial Skin and Skin Structure Infections Market, By Infection Type, 2019 – 2031, (USD Mn)
    • Overview
      • Market Share Analysis, 2024 and 2031 (%)
      • Y-o-Y Growth Analysis, 2019 – 2031
      • Segment Trends
    • Hospital Acquired ABSSSI
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD Mn)
    • Community Acquired ABSSSI
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD Mn)
  7. Global Acute Bacterial Skin and Skin Structure Infections Market, By Route of Administration, 2019 – 2031, (USD Mn)
    • Overview
      • Market Share Analysis, 2024 and 2031 (%)
      • Y-o-Y Growth Analysis, 2019 – 2031
      • Segment Trends
    • Oral
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD Mn)
    • Parenteral
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD Mn)
    • Topical
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD Mn)
  8. Global Acute Bacterial Skin and Skin Structure Infections Market, By Distribution Channel, 2019 – 2031, (USD Mn)
    • Overview
      • Market Share Analysis, 2024 and 2031 (%)
      • Y-o-Y Growth Analysis, 2019 – 2031
      • Segment Trends
    • Hospital Pharmacies
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD Mn)
    • Retail Pharmacies
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD Mn)
    • Online Pharmacies
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD Mn)
  9. Global Acute Bacterial Skin and Skin Structure Infections Market, By Region, 2019 – 2031, (USD Mn)
    • Introduction
      • Market Share Analysis, By Region, 2024 and 2031 (%)
      • Y-o-Y Growth Analysis, For Region, 2019–2031
      • Regional Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2019 - 2031, (USD Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (USD Mn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2019 - 2031, (USD Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (USD Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2019 - 2031, (USD Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (USD Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2019 - 2031, (USD Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (USD Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2019 - 2031, (USD Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (USD Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2019 - 2031, (USD Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 – 2031, (USD Mn)
        • North Africa
        • Central Africa
        • South Africa
  10. Competitive Landscape
    • Company Profiles
      • Fresenius SE & Co. KGaA
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Pfizer, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Amneal Pharmaceuticals LLC
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Intas Pharmaceuticals Ltd.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Cadila Healthcare Ltd.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Glenmark Pharmaceuticals Ltd
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • GSK plc
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Sun Pharmaceutical Industries Ltd.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Aurobindo Pharma Ltd.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • AbbVie, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Melinta Therapeutics, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Accord Healthcare Ltd.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Merck & Co., Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Paratek Pharmaceuticals, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
  11. Analyst Recommendations
    • Wheel of Fortune
    • Analyst View
    • Coherent Opportunity Map
  12. References and Research Methodology
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 38 market data tables and 35 figures on "Acute Bacterial Skin and Skin Structure Infections Market” - Global forecast to 2031

  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2025 Coherent Market Insights Pvt Ltd. All Rights Reserved.